1. Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al. Human pd-l1/b7-h1/cd274 protein. Sino Biological Inc. http://www.sinobiological.com/PD-L1-B7-H1-CD274-Protein-g-533.html . Accessed 2002.
2. Shi L, Chen S, Yang L, Li Y. The role of pd-1 and pd-l1 in t-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013; 6(74):10–118617568722674.
3. Muppidi MR, George S. Immune checkpoint inhibitors in renal cell carcinoma. J Targeted Ther Cancer. 2015; 4:47–52.
4. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, et al. Response to braf inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014; 2(7):643–54.
5. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective braf inhibitors induce marked t-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012; 18(5):1386–94.